Non-Hodgkin's Lymphoma Clinical Trials

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.

Diagnosis: Non-Hodgkin's Lymphoma, Leukemia/MDS

Phase: 3

Protocol Number: 14-179

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

This research study is evaluating a drug combination called Imprime PGG and Rituximab as a possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).

Diagnosis: Non-Hodgkin's Lymphoma

Phase: 2

Protocol Number: 13-398

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard ...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer

Phase: 2

Protocol Number: 15-547

A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

This research study is studying Blinatumomab as a possible treatment for Indolent Non-Hodgkin Lymphoma (NHL).

Diagnosis: Non-Hodgkin's Lymphoma

Phase: 2

Protocol Number: 16-118

Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma

The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

Diagnosis: Solid Tumor/Phase I, Non-Hodgkin's Lymphoma

Phase: 1 / 2

Protocol Number: 15-207

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

The study will examine the safety profile of SGN-CD19B administered as a single agent. The main purpose of the study is to estimate the highest dose that does not cause unacceptable side effects of...

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 16-412

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds t...

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 17-075

Axicabtagene Ciloleucel Expanded Access Study

This is a multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory transplant ineligible aggressive NHL.

Diagnosis: Non-Hodgkin's Lymphoma

Phase:

Protocol Number: 17-125